Long-Term Outcomes from a Phase 2 Trial of Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S58-S59
DOI: 10.1016/j.ijrobp.2026.06.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von X.D. Li und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, X., Garant, A., Robles, L., Kapur, P., Ahn, C., Woldu, S., Margulis, V., Cadeddu, J., Timmerman, R., & Hannan, R. (2026). Long-Term Outcomes from a Phase 2 Trial of Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics, 126(1), S58-S59. https://doi.org/10.1016/j.ijrobp.2026.06.045
Vancouver
Li X, Garant A, Robles L, Kapur P, Ahn C, Woldu S, et al. Long-Term Outcomes from a Phase 2 Trial of Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S58-S59. doi:10.1016/j.ijrobp.2026.06.045
BibTeX
@article{Li2026,
author = {Li, X.D. and Garant, A. and Robles, L. and Kapur, P. and Ahn, C. and Woldu, S. and Margulis, V. and Cadeddu, J. and Timmerman, R.D. and Hannan, R.},
title = {Long-Term Outcomes from a Phase 2 Trial of Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {S58--S59},
doi = {10.1016/j.ijrobp.2026.06.045}
}
EUVIMED